Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold
Nikos Fatsis-Kavalopoulos, Yong Kyun Kim, Yong Pil Chong, Seongman Bae, So Yun Lim, Yang Soo Kim, Dan I Andersson · 2025
Read Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold by Nikos Fatsis-Kavalopoulos, Yong Kyun Kim, Yong Pil Chong, Seongman Bae, So Yun Lim, Yang Soo Kim, Dan I Andersson (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12717272.txt.
Description
Nikos Fatsis-Kavalopoulos and co-authors study a hidden form of drug resistance in a dangerous hospital germ, in a paper from 2025. The germ is MRSA, a staph type that resists many drugs. In some strains, only a small share of cells resist the key drug vancomycin, which makes the trait hard to spot.
The team followed more than eight hundred adults in South Korea with the germ in their blood. The hidden trait appeared in about one in five cases. It linked to hospital-acquired infection and to past drug exposure. Overall, patients with the trait died less often within ninety days. But when they were treated with vancomycin, deaths more than doubled and relapse rose sharply. The authors derive a test threshold that predicts risk.
Catalog record
| CREATOR | Nikos Fatsis-Kavalopoulos, Yong Kyun Kim, Yong Pil Chong, Seongman Bae, So Yun Lim, Yang Soo Kim, Dan I Andersson |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 37 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |